Vaccine Clinical Research Done Right
AMR Clinical’s stellar performance in vaccine trials has earned the company a reputation of excellence across the industry. Our clinical research sites provide uncompromising quality to advance your vaccine innovations.
Mastering the Art of Vaccine Research
AMR Clinical has been recommended by the World Congress’s Vaccine Industry Excellence (ViE) Award for “Best Clinical Trial Site or Network” annually since inception. AMR Clinical is the only site company who is a four-time recipient:
- 1,000+ vaccine studies
- 55,000+ participants enrolled
- 50+ biopharma and government agency clients
- 45 vaccine indications
- 110% average enrollment goals achieved
- 96% average retention rate
Participant Populations
- Disease-specific populations
- Geriatrics
- Healthy volunteer
- Immunocompromised
- Maternal
- Pediatrics (Newborns-Infants-Adolescents)
Clinical Trial Types
- Combination vaccines
- Department of Defense
- First-in-human studies
- Government-funded studies
- Phase I, II, III, and IV
Vaccine Types
- Inactivated vaccines
- Live-attenuated vaccines
- Messenger RNA (mRNA) vaccines
- Subunit, recombinant, polysaccharide, and conjugate vaccines
- Toxoid vaccines
- Viral vector vaccines
Research Done Right — Vaccine/Disease Indications
- Adenovirus
- Anthrax
- Avian influenza (H5N1)
- BCG (tuberculosis)
- Botulism
- Candidiasis
- Canine influenza (H3N2)
- Chikungunya
- Cholera
- Clostridium difficile
- Coronavirus (COVID-19)
- Cytomegalovirus
- Dengue fever
- Diphtheria
- E. coli
- Ebola
- Epstein-Barr
- Hemorrhagic fever
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Herpes simplex
- Herpes zoster
- HIV
- Human metapneumovirus (hMPV)
- Human papillomavirus (HPV)
- Hypertension
- Influenza (seasonal and pandemic)
- Lassa fever
- Lyme disease
- Malaria
- Marburg
- Measles
- Melanoma
- Meningococcal ACWY
- Meningococcal B
- MERS
- MMR (measles, mumps, rubella)
- Monkeypox
- MRSA
- mRNA vaccines
- Nipah virus
- Norovirus
- Orthopox
- Peanut allergy
- Pertussis
- Plague
- Pneumococcal
- Polio
- Rabies
- Respiratory infection
- Respiratory syncytial virus
- Rhinovirus
- Sepsis
- Shigella
- Sjogren’s syndrome
- Smallpox
- Smoking cessation
- Staphylococcus
- Strep pharyngitis
- Swine flu (H1N1)
- Tetanus (Tdap)
- Urinary tract infection (UTI)
- Varicella
- Viral syndrome
- Yellow fever
- West Nile virus
- Zika virus
Recent Vaccine Approvals
| Sponsor | Asset | Indication | Population |
|---|---|---|---|
| AstraZeneca/Sanofi | Beyfortus | RSV vaccine | Infants |
| AstraZeneca | Flumist | Influenza A and B viruses | Adult/Pediatrics |
| AstraZeneca | Vaxzevria | SARS CoV 2 | Adults |
| bioCSL | Optaflu | Influenza vaccine | Adults |
| GSK | Arexzvy | RSV vaccine | Adult |
| GSK | Fluarix | Influenza A and B viruses | Adult/Pediatrics |
| GSK | Penmenvy | Pentavalent meningococcal vaccine | Adult/Adolescents |
| Merck/Sanofi | Vaxelis | Hexavalent DTaP, IPV, Hib, HepB | Pediatrics |
| Moderna | Spikevax | COVID-19 mRNA vaccine | Adult/Adolescent |
| ModernaTX | mResvia | RSV vaccine | Older Adults |
| NIH/NIAID | Visby Lancet diagnostic | Detection of STIs | Adult/Adolescent |
| Novavax | Nuvaxovid | COVID-19 vaccine | Adult/Adolescent |
| OraSure Technologies | Orasure Device for HIV | HIV-1 antibody testing | Adult/Adolescent |
| Pfizer | Abrysvo | RSV vaccine | Adult |
| Pfizer | Comirnaty | COVID-19 mRNA vaccine | Adult/Adolescent |
| Pfizer | Paxlovid | Mild-moderate COVID-19 | Adult/Pediatrics |
| Pfizer | Penbraya | Pentavalent meningococcal vaccine | Pediatrics/Adolescents |
| Pfizer | Prevnar20 | 20-valent pneumococcal vaccine | Pediatric |
| Sanofi | Flublok | Influenza A and B viruses | Adult |
| Sanofi | Flulaval | Influenza A and B viruses | Adult/Pediatrics |
| Sanofi | Fluzone High-Dose | Influenza A and B viruses | Older Adults |
| Sanofi | MenQuadfi | Meningococcal vaccine | Pediatrics |
